These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 25027751)

  • 1. Luteal phase support with gonadotropin-releasing hormone agonist.
    Tsui KH; Lin LT; Wang PH
    J Chin Med Assoc; 2014 Oct; 77(10):505-7. PubMed ID: 25027751
    [No Abstract]   [Full Text] [Related]  

  • 2. Luteal phase support with decapeptyl improves pregnancy outcomes in intracytoplasmic sperm injection with higher basal follicle-stimulating hormone or lower mature oocytes.
    Kung HF; Chen MJ; Guua HF; Chen YF; Yi YC; Yen-Ping Ho J; Chou MM
    J Chin Med Assoc; 2014 Oct; 77(10):524-30. PubMed ID: 25160805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does lower dose of long-acting triptorelin maintain pituitary suppression and produce good live birth rate in long down-regulation protocol for in-vitro fertilization?
    Chen X; Feng SX; Guo PP; He YX; Liu YD; Ye DS; Chen SL
    J Huazhong Univ Sci Technolog Med Sci; 2016 Apr; 36(2):215-220. PubMed ID: 27072965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function.
    DiLuigi AJ; Nulsen JC
    Curr Opin Obstet Gynecol; 2007 Jun; 19(3):258-65. PubMed ID: 17495643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
    Krause BT; Ohlinger R
    Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single dose GnRH agonist administration in the luteal phase of assisted reproduction cycles: is the effect dependent on the type of GnRH analogue used for pituitary suppression?
    Ata B; Urman B
    Reprod Biomed Online; 2010 Jan; 20(1):165-6; author reply 167. PubMed ID: 20159003
    [No Abstract]   [Full Text] [Related]  

  • 11. Beneficial effect of luteal-phase gonadotropin-releasing hormone agonist administration on implantation rate after intracytoplasmic sperm injection.
    Razieh DF; Maryam AR; Nasim T
    Taiwan J Obstet Gynecol; 2009 Sep; 48(3):245-8. PubMed ID: 19797013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantation rates subsequent to the transfer of embryos produced at different phases during double stimulation of poor ovarian responders.
    Zhang Q; Guo XM; Li Y
    Reprod Fertil Dev; 2017 Jun; 29(6):1178-1183. PubMed ID: 27166216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial.
    Gizzo S; Andrisani A; Esposito F; Noventa M; Di Gangi S; Angioni S; Litta P; Gangemi M; Nardelli GB
    Gynecol Endocrinol; 2014; 30(12):902-8. PubMed ID: 25268567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mid-luteal phase GnRH agonist on frozen-thawed embryo transfers during natural menstrual cycles: a randomised clinical pilot study.
    Seikkula J; Anttila L; Polo-Kantola P; Bloigu R; Engblom J; Tinkanen H; Jokimaa V
    Gynecol Endocrinol; 2016 Dec; 32(12):961-964. PubMed ID: 27348542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GnRH agonist protocol administration in the luteal phase in ICSI-ET cycles stimulated with the long GnRH agonist protocol: a randomized, controlled double blind study.
    Ata B; Yakin K; Balaban B; Urman B
    Hum Reprod; 2008 Mar; 23(3):668-73. PubMed ID: 18192671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Flare-up study and gonadotropin extinction curve in patients treated with long-acting triptorelin, 3.75 mg im].
    Vizziello G; D'Amato G; Trentadue R; Fanizza G
    Ann Ostet Ginecol Med Perinat; 1993; 113(3):143-7. PubMed ID: 8328767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of luteal-phase gonadotropin-releasing hormone agonist administration on pregnancy outcome in IVF/ICSI cycles: a systematic review and Meta-analysis].
    Yu LP; Liu N; Liu Y
    Zhonghua Fu Chan Ke Za Zhi; 2016 Nov; 51(11):850-858. PubMed ID: 27916070
    [No Abstract]   [Full Text] [Related]  

  • 19. The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation with progesterone or progesterone and estradiol.
    Fatemi HM; Camus M; Kolibianakis EM; Tournaye H; Papanikolaou EG; Donoso P; Devroey P
    Fertil Steril; 2007 Mar; 87(3):504-8. PubMed ID: 17140572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GnRH agonist plus vaginal progesterone for luteal phase support in ICSI cycles: a randomized study.
    Aboulghar MA; Marie H; Amin YM; Aboulghar MM; Nasr A; Serour GI; Mansour RT
    Reprod Biomed Online; 2015 Jan; 30(1):52-6. PubMed ID: 25456166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.